In8bio recently announced its financial results for the third quarter of 2024, highlighting significant advancements in its INB-100 program for AcuteMyeloidLeukemia (AML). The company reported ...
A treatment of acutemyeloidleukemia being developed by Sanofi (SNY) US Services was granted FDA orphan designation, according to a post to the agency’s website. Published first on TheFly – the ...